RUBICON

- Q1 FY27 Consolidated Revenue ₹534Cr (▲51% YoY). - EBITDA ₹131Cr (▲65% YoY), PAT ₹85Cr (▲>95% YoY). - Operating EBITDA Margin expanded to 24.2% from 22.4% YoY. - FY27 EBITDA margin guidance revised upwards from 22-23% to 23%. - Arinna acquisition contributed ₹12Cr to Q1 FY27 revenue, with no material EBITDA impact. - Acquired New Jersey manufacturing facility for USD 2.9 million; FDA inspection received VAI status, commercialization expected from calendar year 2027. - Pithampur facility's FDA inspection observations resolved, operations to ramp up from Q1 calendar year 2027. - Nitin Jajodia (CFO) transitioned to Chief Commercial Officer; a new CFO, Rohit, will be joining. - R&D spend target of ₹500Cr over FY26, FY27, and Q1 FY28 is on track. - Q1 operating cash flow impacted by delayed GST refunds, expected to normalize in Q2.

- Audio recording of the earnings conference call for the quarter ended 30th June, 2026 is available. - The recording can be accessed at https://rubicon.co.in/pdf/corporate-announcement/10046305.mp3

- Mr. Rohit Saraogi appointed as Chief Financial Officer (CFO) Designate, effective August 14, 2026. Current CFO, Mr. Nitin Jajodia, transitions to Chief Commercial Officer (CCO). - Mr. Venkat Changavalli re-appointed as Chairman, extending his term from September 18, 2026, to June 10, 2027.

- Q1 FY27 Consolidated Revenue ₹534.3Cr vs ₹352.5Cr (▲51.6% YoY) - EBITDA ₹131.2Cr vs ₹79.7Cr (▲64.6% YoY) - PAT ₹84.8Cr vs ₹43.3Cr (▲95.8% YoY) - EBITDA Margin 24.6% vs 22.6% (▲200bps)

- Q1 FY27 Consolidated Revenue ₹5,343Mn vs ₹3,525Mn (▲51.6% YoY) - EBITDA ₹1,312Mn vs ₹797Mn (▲64.6% YoY) - PAT ₹848Mn vs ₹433Mn (▲95.8% YoY) - EBITDA Margin 24.6% vs 22.6% (▲200bps)

- Q1 FY27 Consolidated Revenue ₹5,343.38Mn vs ₹3,524.94Mn (▲51.58% YoY) - EBITDA ₹1,291.16Mn vs ₹791.11Mn (▲63.21% YoY) - PAT ₹847.81Mn vs ₹433.01Mn (▲95.79% YoY) - EBITDA Margin 24.16% vs 22.44% (▲172bps)

- Concall Schedule - Concall Date: Friday, August 14, 2026 - Concall Time (India): 06:00 PM

- Submission of Business Responsibility and Sustainability Report for FY 2025-26 as part of Integrated Annual Report. - The report details ESG initiatives, policies, and commitments. - Company reported turnover of ₹13,060.82 Million and net worth of ₹13,209.83 Million for FY 2025-26. - Exports contributed 98.44% of total turnover.

- Communication regarding Tax Deduction at Source (TDS) on the final dividend of ₹1.50 per Equity Share for FY 2025-26. - Dividend is subject to shareholder approval at the AGM on August 26, 2026. - Record Date for dividend is August 7, 2026. - Shareholders must update KYC and submit declarations/certificates by August 10, 2026, for appropriate TDS calculation as per Income Tax Act, 2025.

- Rubicon Research Limited announced the merger of its wholly-owned subsidiary, Kia Health Tech Private Limited, with the parent company. - The Board approved the Scheme of Merger on July 20, 2026, with an Appointed Date of April 1, 2026. - Rationale includes business synergy, resource optimization, reduced compliance, and enhanced operational efficiency. No change in shareholding or issuance of new shares.

- Rubicon Research Limited (via subsidiary AdvaGen Holdings' Inc.) acquired a manufacturing facility in East Brunswick, New Jersey, USA from InvaTech Pharma Solutions, LLC for an enterprise value of USD 2.9 million. This acquisition, completed on July 21, 2026, provides Rubicon with a US manufacturing footprint. The company expects to commence manufacturing at the site in calendar year 2027 and plans significant capital investments over the next 3 years to expand capabilities.

- Board meeting held on July 20, 2026, approved 27th Annual General Meeting (AGM) on August 26, 2026. - Fixed Record Date as August 7, 2026, for the final dividend payment of ₹1.50 per equity share for FY 2025-26. - Approved the merger of Kia Health Tech Private Limited (a wholly-owned subsidiary) with the company, effective April 1, 2026, with no change in shareholding.

- Board Meeting held on July 20, 2026. - Recommended a final dividend of ₹1.50 per equity share for FY 2025-26. - Fixed August 7, 2026, as the Record Date for dividend payment. - Scheduled 27th Annual General Meeting (AGM) for August 26, 2026. - Approved the scheme of merger of wholly-owned subsidiary Kia Health Tech Private Limited with the company, effective April 1, 2026.

- On July 20, 2026, Rubicon Research allotted 1,49,158 fully paid-up equity shares pursuant to the exercise of employee stock options under its ESOP Scheme 2022. - Consequently, the company's issued and paid-up equity share capital increased to INR 16,55,31,908, comprising 16,55,31,908 equity shares of face value INR 1 each.